IRLAB receives approval from the Finnish MPA (Fimea)

October 5, 2017

IRLAB Therapeutics AB has now received approval from Fimea (the Finnish MPA) and the Ethics Committee at the University hospital in Turkku to conduct the Phase II clinical trial with IRL752 in Finland. On august 25, 2017, IRLAB received approval from the Swedish MPA to start the study in Sweden.

IRLAB Therapeutics AB has now received approval from Fimea (the Finnish MPA) and the Ethics Committee at the University hospital in Turkku to conduct the Phase II clinical trial with IRL752 in Finland. On august 25, 2017, IRLAB received approval from the Swedish MPA to start the study in Sweden.

“It is highly pleasing that yet another Competent Authority, the Finnish MPA, has reviewed our candidate drug IRL752 and given their clinical trial approval. Now the study can recruit patients in both Sweden and Finland. In addition, we get to collaborate with highly skilled Finnish experts with vast experience of Parkinson’s disease” says Joakim Tedroff, IRLAB’s chief medical officer, CMO.

The randomized, double-blind, placebo controlled Phase II study is designed to study effects of IRL752 on cognitive and motor symptoms in patients with Parkinson’s disease and dementia. The primary objective is to study safety and tolerability of IRL752 in this patient population.

Documents & Links